GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinus Pharmaceuticals Inc (NAS:MRNS) » Definitions » Property, Plant and Equipment

MRNS (Marinus Pharmaceuticals) Property, Plant and Equipment : $4.88 Mil (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Marinus Pharmaceuticals Property, Plant and Equipment?

Marinus Pharmaceuticals's quarterly net PPE declined from Mar. 2024 ($3.74 Mil) to Jun. 2024 ($3.72 Mil) but then increased from Jun. 2024 ($3.72 Mil) to Sep. 2024 ($4.88 Mil).

Marinus Pharmaceuticals's annual net PPE increased from Dec. 2021 ($2.50 Mil) to Dec. 2022 ($4.24 Mil) but then declined from Dec. 2022 ($4.24 Mil) to Dec. 2023 ($3.84 Mil).


Marinus Pharmaceuticals Property, Plant and Equipment Historical Data

The historical data trend for Marinus Pharmaceuticals's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinus Pharmaceuticals Property, Plant and Equipment Chart

Marinus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Property, Plant and Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.27 1.95 2.50 4.24 3.84

Marinus Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.91 3.84 3.74 3.72 4.88

Marinus Pharmaceuticals Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Marinus Pharmaceuticals  (NAS:MRNS) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Marinus Pharmaceuticals Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Marinus Pharmaceuticals's Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Marinus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Matsonford Road, Suite 500, 5 Radnor Corporate Center, Radnor, PA, USA, 19087
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Executives
Christina Shafer officer: Chief Commercial Officer 5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD ROAD, RADNOR PA 19087
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Steven Pfanstiel officer: CFO 5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087
Joseph Hulihan officer: Chief Medical Officer 5 RADNOR CORP CENTER SUITE 500, 100 MATSONFORD RD, RADNOR PA 19087
Martha E Manning officer: VP, Gen. Counsel & Corp. Sec. 700 PENNSYLVANIA DR, EXTON PA 19341
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Marvin Johnson director C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Elan Ezickson director AVEO PHARMACEUTICALS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Charles Austin director 5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Christine Berni Silverstein director C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Santiago Arroyo director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Sara Nochur director 295 WOODCLIFF RD, NEWTON MA 02461
Nicole Vitullo director, 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Edward F Smith officer: Chief Financial Officer C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104